Click here to read the press release on Business Wire.
Canton, MA, USA, Cambridge, MA, USA, and Rotterdam, the Netherlands, July 1, 2019 - Abveris, Inc., a global leader in contract research antibody discovery, and Harbour Antibodies H2L2 BV, a wholly-owned subsidiary of Harbour BioMed, today announced a partnership to offer fully-human antibody discovery service that combines Abveris’ antibody discovery services with the Harbour H2L2 human transgenic mouse platform. The combined offering eliminates the need for antibody humanization through the use of the H2L2 Harbour Mice™, and benefits from Abveris’ full suite of therapeutic antibody discovery capabilities.
Abveris was selected as a designated CRO to offer its fully-human antibody discovery service under the Co-Offering Agreement utilizing the H2L2 Harbour Mice™. The Co-Offering Agreement with Harbour includes a low-upfront evaluation fee and pre-negotiated commercial terms that Abveris can in turn provide to partners. The new Co-Offering allows Abveris clients to assess the H2L2 human transgenic mouse technology before committing to a full commercial license.
“We have historically generated potent, fully-human antibodies using the H2L2 Harbour Mice™. This program will allow us to continue to offer H2L2 antibody discovery with the elimination of contractual barriers for our biopharma partners seeking fully-human antibody discovery,” said Garren Hilow, CEO of Abveris. “We look forward to continuing our partnership with Harbour to use the H2L2 Harbour Mice™ in both our hybridoma platform and our AbX Biologics single B-cell discovery platform.”
“We are really excited about this Agreement which allows us to offer our partners access to this leading technology platform in the form of the H2L2 Harbour Mice™. It is an integral part of our strategy to build truly innovative products both in-house and with our partners, and the partnership with Abveris will further allow us to better fulfill unmet medical needs for patients worldwide,” said Jingsong Wang, MD, Ph.D., Chairman & CEO of Harbour BioMed.
Harbour’s patented H2L2 mouse platform provides antibody generation through a natural in vivo process, allowing for the generation of diversified, affinity-matured, human antibody repertoires. Harbour Mice™ licensees include over 40 multinational pharmaceutical, biotechnology, and academic institutions. Abveris will leverage this platform in combination with its own proprietary immunization and high-throughput characterization capabilities to provide a fully-human therapeutic antibody discovery offering to its growing customer base.
Abveris is a premium Boston-area contract research organization specializing in antibody discovery. Abveris partners with large and small biopharmaceutical companies to discover novel therapeutic products and critical reagent antibodies using diverse platforms, including the proprietary DiversimAb™ hyperimmune mouse technology and a variety of humanized mice. Additional information about Abveris is available at www.abveris.com
Ryan Kelly, MBA
480 Neponset Street, Suite 10B
Canton, MA 02021, USA
About Harbour Antibodies:
Harbour Antibodies H2L2 BV is a fully owned subsidiary of Harbour BioMed, a global biopharmaceutical company discovering and developing innovative therapeutics for oncology and immunological diseases (www.harbourbiomed.com). Harbour Antibodies owns two strains of transgenic mice for generating human therapeutic antibodies: (1) mice that generate antibodies comprised of two heavy chains and two light chains (H2L2) with fully human variable regions; and (2) mice that generate novel “heavy chain only” antibodies (HCAb). The HCAb mice enable the development of antibody fragment-based therapeutics such as nanobodies, bi-specific antibodies and CAR-T with favorable drug-like properties. For additional information, please visit www.harbourantibodies.com
Jung Lee, Ph.D.
Cambridge, MA 02142, USA